• P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

Ligand Based Multi-Targeted Molecular Docking Analysis o f Terpenoid Phytoconstituents as Potential Chemotherapeutic Agents Against Breast Cancer: An In Silico Approach
  • VIEWS 382
  • PDF 116

Journal of Pharmaceutical Research

DOI: 10.18579/jopcr/v22.2.23.5

Year: 2023, Volume: 22, Issue: 2, Pages: 55-62

Original Article

Ligand Based Multi-Targeted Molecular Docking Analysis o f Terpenoid Phytoconstituents as Potential Chemotherapeutic Agents Against Breast Cancer: An In Silico Approach

Senthil Kumar Raju ​✉ 1 , Shridharshini Kumar 1 , Praveen Sekar 1 , Naveena Sundhararajan 1 , Yogadharshini Nagalingam 1

 
1 Department of Pharmaceutical Chemistry, Swamy Vivekanandha College of Pharmacy, Tiruchengode, Tamilnadu, 637 205, India

Corresponding author ✉: [email protected]

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Breast cancer is one of the most common cancers in women all around the world and is a dominant cause of deaths occurring all around the globe. The available potent drugs for breast cancer show adverse effects and resistance and are found to be ineffective in patients. The high cost of currently available cancer therapy and certain limitations of current treatment make it necessary to search for novel, cost-effective and efficient methods of cancer treatment. Phytochemicals are directly involved in treatment or precursors to synthesize useful drugs. Therefore, in the current investigation, 500 terpenoid phytoconstituents and five proteins associated with breast cancer including EGFR, ERα, HER2, NF-κB and Topo IIa were selected from various databases. Selected compounds were screened for their molecular properties based on Lipinski's rule of five resulting in 235 compounds exclusion. Drug-likeness and PAINS alert properties were predicted using pkCSM and SwissADME web servers which led to the omission of 43 compounds. The remaining 222 compounds were screened to predict their ADMET properties and based on these results, 117 compounds were selected to predict the anti-breast cancer potential. Finally, 73 compounds, which showed anti-breast cancer activity prediction, were virtually screened and the top four best-scoring compounds were selected as lead-like molecules and docked with the five respective breast cancer targets. The results showed that the top four lead-like molecules exhibited greater binding affinity and lesser toxicity than the standard drugs namely 4–Hydroxytamoxifen, Daunorubicin, Erlotinib and Lapatinib.

Keywords: ADMET, Breast cancer, Chemotherapeutic agents, In silico analysis, Molecular docking, Terpenoids

References

  1. Raju SK, Karunakaran A, Kumar S, Sekar P, Murugesan M, Karthikeyan M. Silver Complexes as Anticancer Agents: A Perspective Review. German Journal of Pharmaceuticals and Biomaterials. 2022;1(1):06–28. Available from: https://doi.org/10.5530/gjpb.2022.1.3
  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians. 2013;63(1):11–30. Available from: https://doi.org/10.3322/caac.21166
  3. Chhikara BS, Parang K. Global Cancer Statistics 2022: the trends projection analysis. Chemical Biology Letters. 2023;10(1):1–16. Available from: https://pubs.thesciencein.org/journal/index.php/cbl/article/view/451/293
  4. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023;73(1):17–48. Available from: https://doi.org/10.3322/caac.21763
  5. Kamdje AHN, Etet PFS, Vecchio LF, Muller JM, Krampera MM, Lukong KE. Signaling pathways in breast cancer: Therapeutic targeting of the microenvironment. Cellular Signalling. 2014;26(12):2843–2856. Available from: https://doi.org/10.1016/j.cellsig.2014.07.034
  6. Lukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. Cancers . 2021;13(17):1–30. Available from: https://doi.org/10.3390/cancers13174287
  7. Kerr AJ, Dodwell D, Mcgale P, Holt F, Duane F, Mannu GF, et al. Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. Cancer Treatment Reviews. 2022;105:1–12. Available from: https://doi.org/10.1016/j.ctrv.2022.102375
  8. Elkaeed EB, Salam HAAE, Sabt A, Al-Ansary GH, Eldehna WM. Recent Advancements in the Development of Anti-Breast Cancer Synthetic Small Molecules. Molecules. 2021;26(24):1–31. Available from: https://doi.org/10.3390/molecules26247611
  9. Koury J, Zhong L, Hao J. Targeting Signaling Pathways in Cancer Stem Cells for Cancer Treatment. Stem Cells International. 2017;2017:1–10. Available from: https://doi.org/10.1155/2017/2925869
  10. Sikander M, Hafeez BB, Malik S, Alsayari A, Halaweish FT, Yallapu MM, et al. Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer. Scientific Reports. 2016;6(1):1–13. Available from: https://doi.org/10.1038/srep36594
  11. Zhang L, Wang H. Multiple Mechanisms of Anti-Cancer Effects Exerted by Astaxanthin. Marine Drugs. 2015;13(7):4310–4330. Available from: https://doi.org/10.3390/md13074310
  13. Yang W, Chen X, Li Y, Guo S, Wang Z, Yu X. Advances in Pharmacological Activities of Terpenoids. Natural Product Communications. 2020;15(3):1–13. Available from: https://doi.org/10.1177/1934578X20903555
  15. El-Baba C, Baassiri A, Kiriako G, Dia B, Fadlallah S, Moodad S, et al. Terpenoids’ anti-cancer effects: focus on autophagy. Apoptosis. 2021;26:491–511. Available from: https://doi.org/10.1007/s10495-021-01684-y
  16. Zeng T, Liu Z, Zhuang J, Jiang Y, He W, Diao H, et al. TeroKit: A Database-Driven Web Server for Terpenome Research. Journal of Chemical Information and Modeling. 2020;60(4):2082–2090. Available from: https://doi.org/10.1021/acs.jcim.0c00141
  17. Williams CJ, Headd JJ, Moriarty NW, Prisant MG, Videau LL, Deis LN, et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Science. 2018;27(1):293–315. Available from: https://doi.org/10.1002/pro.3330
  18. Chen Y, Zhu Z, Chen J, Zheng Y, Limsila B, Lu M, et al. Terpenoids from Curcumae Rhizoma: Their anticancer effects and clinical uses on combination and versus drug therapies. Biomedicine & Pharmacotherapy. 2021;138:1–31. Available from: https://doi.org/10.1016/j.biopha.2021.111350
  19. Fan M, Yuan S, Li L, Zheng J, Zhao D, Wang C, et al. Application of Terpenoid Compounds in Food and Pharmaceutical Products. Fermentation. 2023;9(2):1–17. Available from: https://doi.org/10.3390/fermentation9020119
  21. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry. 2009;30(16):2785–2791. Available from: https://doi.org/10.1002/jcc.21256
  22. Gaur AS, Bhardwaj A, Sharma A, John L, Vivek MR, Tripathi N, et al. Assessing therapeutic potential of molecules: molecular property diagnostic suite for tuberculosis (MPDSTB) Journal of Chemical Sciences. 2017;129(5):515–531. Available from: https://doi.org/10.1007/s12039-017-1268-4
  23. Pacey S, Workman P, Sarker D. Pharmacokinetics and Pharmacodynamics in Drug Development. In: Encyclopedia of Cancer. (pp. 2845-2848) Springer Berlin Heidelberg. 2011.
  24. Neumaier F, Zlatopolskiy BD, Neumaier B. Drug Penetration into the Central Nervous System: Pharmacokinetic Concepts and In Vitro Model Systems. Pharmaceutics. 2021;13(10):1–31. Available from: https://doi.org/10.3390/pharmaceutics13101542
  25. Fink C, Sun D, Wagner K, Schneider M, Bauer H, Dolgos H, et al. Evaluating the Role of Solubility in Oral Absorption of Poorly Water‐Soluble Drugs Using Physiologically‐Based Pharmacokinetic Modeling. Clinical Pharmacology & Therapeutics. 2020;107(3):650–661. Available from: https://doi.org/10.1002/cpt.1672
  27. Morales AM, Mukai R, Murota K, Terao J. Inhibitory effect of catecholic colonic metabolites of rutin on fatty acid hydroperoxide and hemoglobin dependent lipid peroxidation in Caco-2 cells. Journal of Clinical Biochemistry and Nutrition. 2018;63(3):175–180. Available from: https://doi.org/10.3164/jcbn.18-38
  28. Pires DEV, Kaminskas LM, Ascher DB. Prediction and Optimization of Pharmacokinetic and Toxicity Properties of the Ligand. Methods in Molecular Biology. 2018;1762:271–284. Available from: https://link.springer.com/protocol/10.1007/978-1-4939-7756-7_14
  30. Mortelmans K, Zeiger E. The Ames Salmonella/microsome mutagenicity assay. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2000;455(1-2):29–60. Available from: https://doi.org/10.1016/S0027-5107(00)00064-6
  31. Zhang X, Liu T, Li Q, Li M, Du L. Aggregation-Induced Emission: Lighting Up hERG Potassium Channel. Frontiers in Chemistry. 2019;7(54):1–6. Available from: https://doi.org/10.3389/fchem.2019.00054

Copyright

© 2023 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/) 

  • 16 September 2023

Year: 2023, Volume: 22, Issue: 2


More articles

DON'T MISS OUT!

Subscribe now for latest articles and news.